Trial Profile

A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2017 Results of a subgroup analysis of CHAMPION PCI, CHAMPION PLATFORM and CHAMPION PHOENIX trials (n=24,902) in patients who did not receive Glycoprotein IIb/IIIa Inhibitors, presented in the Journal of the American College of Cardiology
24 Aug 2015 According to The Medicines Company media release, data from this study will be presented at the 2015 European Society of Cardiology (ESC) Congress.
14 Nov 2014 The Medicines Company plans to resubmit an NDA for cangrelor by the end of 2014 with respect to the PCI indication, according to a media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com